-
About Biosimilar
I will explain biosimilars in an easy-to-understand manner.
-
Our Products
We introduce our products.
-
About us
Basic corporate data for FUJIFILM KYOWA KIRIN BIOLOGICS.
-
Solution
We will explain our strengths of handling biosimilars.
What's New
- Feb. 15, 2021
- Fujifilm Kyowa Kirin Biologics and Mylan EPD Announce Launch of Biosimilar Adalimumab in Japan (PDF: 512KB)
- Sep. 29, 2020
- Centus Biotherapeutics Receives European Marketing Authorization for Equidacent®, Biosimilar Avastin® (PDF: 76KB)
- Jul. 27, 2020
- Centus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab (PDF: 492KB)
- Jul. 9, 2020
- Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp) (PDF: 490KB)
- Jun. 29, 2020
- Fujifilm Kyowa Kirin Biologics Announces Approval of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan (PDF: 409KB)